Tests mesopancreatic excision during surgery for pancreatic duct cancer
Tests a wider tissue removal during pancreas surgery in adults with pancreatic duct cancer.
Key facts
- Who runs it
- Minia University
- Where
- Minya, EgyptSee the site
- Trial code
- Registry title
- Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 Apr 2024
- Expected to end
- 1 May 2027
- Type of study
- Interventional
- Treatments tested
- Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic cancer of the pancreatic head that can be removed by surgery, and who are planned for pancreaticoduodenectomy with mesopancreatic excision.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Pancreatic ductal adenocarcinoma of the pancreatic head, confirmed by biopsy. The tumour must be resectable: no distant metastases, no arterial involvement over 180°, and veins that can be reconstructed.
- Earlier treatment
- No earlier chemotherapy or radiotherapy before surgery (this may be changed for some subgroups). No earlier radiotherapy to the abdomen.
Main reasons for not taking part
- Borderline resectable or unresectable pancreatic cancer
- Distant metastases
- Periampullary tumours other than pancreatic adenocarcinoma
- Active second cancer
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥18 years
- Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision
- Histologically confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided biopsy)
- Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant metastases, no arterial involvement >180°, venous involvement reconstructable)
- Eastern Cooperative Oncology Group(ECOG) performance status 0-2
- Adequate organ function (e.g., bilirubin <1.5x upper limit of normal(ULN), creatinine clearance >50 mL/min)
- Informed consent
Who cannot take part
- Prior neoadjuvant chemotherapy or radiotherapy (to isolate TMpE effect; may be amended for subgroups)
- Patients who have received prior radiotherapy to the abdomen
- Active second malignancy
- Severe comorbidities precluding surgery (e.g., uncontrolled cardiac disease)
- Borderline resectable or unresectable PDAC
- Distant metastases
- Periampullary tumors other than pancreatic adenocarcinoma
- Pregnancy or lactation
- Patients unwilling or unable to provide informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Egypt
- Liver and GIT hospital , Minia UniversityMinya, EgyptContact: Saleh K Saleh, MDTaking people
About the trial
What the trial wants to find out
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis.
Read full original descriptionShow less
Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local recurrence, and enhance overall survival compared to standard pancreatoduodenectomy. However, most existing studies are retrospective with heterogeneous patient populations and surgical techniques.
This prospective study aims to evaluate the impact of mesopancreatic excision, a surgical technique involving the meticulous removal of retroperitoneal tissue surrounding major peripancreatic vessels, on local disease control and overall survival in patients undergoing pancreaticoduodenectomy for resectable PDAC. The study will also assess R0 resection rates, disease-free survival, recurrence patterns and perioperative outcomes.
The group in the trial
- Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)Treatment being tested
En bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels and the celiac axis, performed during pancreaticoduodenectomy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma on Local Disease Control and Survival.
- Plain-language title
- Tests mesopancreatic excision during surgery for pancreatic duct cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07148830, who can take part
- Record updated
- 11 September 2026